An FDA panel voted on six peptides. That is not approval.
A committee can recommend. The agency still has to write a rule. Until then, the legal landscape did not change.
FDA’s Pharmacy Compounding Advisory Committee (PCAC) met on July 23–24, 2026. It recommended six peptides for the 503A Bulks List: BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon. It voted against emideltide (also called DSIP).
On day 1 (July 23), BPC-157, KPV, and TB-500 each went 8–6 with 1 abstention. MOTS-c went 7–5 with 2 abstentions. Free base and acetate were voted separately on several of these.
FDA scientific staff had recommended against including all seven, citing short, small studies and insufficient safety and effectiveness data. BPC-157 was evaluated for ulcerative colitis. TB-500 was evaluated for wound healing.
A PCAC recommendation is not FDA approval and does not put a substance on the 503A Bulks List. FDA would still need notice-and-comment rulemaking — a proposed rule, comment, and a final rule. FDA is not required to follow the committee. None of these peptides is an FDA-approved drug.
Related: What people mean by BPC-157 and TB-500.
Citations
- FDA briefing introduction
- FDA BPC-157 briefing
- FDA introductory remarks, July 23
- AJMC recap
- McDermott law recap
- Mintz: what the vote does and does not do
Peptide Vault is a personal log and research library. Not medical advice, not a pharmacy, not a shop. We do not tell you what to take, how to mix it, or where to get it. No dosing. No where-to-buy. No mix tutorials. No heal/optimize claims.